Over the last decade, the treatment of advanced melanoma has been significantly changed with the development of targeted therapy and immunotherapy. Now, we finally have five-year survival data for both kinds of treatments. How do these results impact daily clinical practice? MEDtalks brings you an on demand e-learning (recorded on January 21st, 2020), in which a Belgian expert panel discusses first and second line treatment of advanced melanoma with targeted therapy and immunotherapy. Furthermore, the burning question on everybody’s mind after the presentation of the five-year survival results of the CheckMate 067 trial is of course not left untouched: should patients be treated with combination immunotherapy or monotherapy? And besides this systemic armamentarium, what is the role of local treatment options in the current treatment of (brain) metastasized melanoma? Panel members Prof. Bart Neyns, MD, PhD - medical oncologist, University Hospital of Brussels Prof. Vibeke Kruse, MD, PhD - medical oncologist, Ghent University Annemie Rutten, MD, PhD - medical oncologist, GZA Hospital Sint-Augustinus Prof. Dirk van Gestel, MD, PhD - radiation oncologist, Institut Jules Bordet Subjects (among others) Five-year survival rate of targeted therapy and immunotherapy; First and second line systemic treatment of advanced melanoma; Combination immunotherapy versus monotherapy anti-PD1 subsequently followed by anti-CTLA4; Management of patients with poor prognostic factors (e.g. brain metastases) with both systemic and local therapy. Accreditation will be requested for medical oncologists in both Belgium and the Netherlands. Points are credited as soon as accreditation has been granted.